M&A forever changed the medtech landscape in 2015 as companies eyed scale to cope with a new normal of reduced reimbursements, pricing pressure and outcome-based business models.
Solid, steady growth is forecast for the IVD market but point-of-care testing
is expected to challenge the central lab approach to in-vitro assays as the sector matures.